Regeneron Pharmaceuticals, Inc.
REGN
$896.82
$2.830.32%
| Weiss Ratings | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Good | |||
| Risk Grade | B- | |||
| Reward Grade | B | |||
| Rating Factors | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Good | |||
| Beta / Standard Deviation | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.65 | |||
| Price History | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.15% | |||
| 30-Day Total Return | -6.93% | |||
| 60-Day Total Return | -5.23% | |||
| 90-Day Total Return | 6.54% | |||
| Year to Date Total Return | -0.03% | |||
| 1-Year Total Return | 11.97% | |||
| 2-Year Total Return | 25.10% | |||
| 3-Year Total Return | 81.05% | |||
| 5-Year Total Return | 171.40% | |||
| 52-Week High % Change | -9.73% | |||
| 52-Week Low % Change | 31.60% | |||
| Price | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $998.33 | |||
| 52-Week Low Price | $684.81 | |||
| 52-Week Low Price (Date) | Jun 28, 2023 | |||
| 52-Week High Price (Date) | Feb 28, 2024 | |||
| Valuation | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 96.84B | |||
| Enterprise Value | 83.39B | |||
| Price/Earnings (TTM) | 25.93 | |||
| Earnings Per Share (TTM) | 34.75 | |||
| Earnings Per Share Growth | -9.11% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 7.82 | |||
| Price/Book (Q) | 3.72 | |||
| Enterprise Value/Revenue (TTM) | 6.36 | |||
| Price | $904.70 | |||
| Enterprise Value/EBITDA (TTM) | 17.92 | |||
| Enterprise Value/EBIT | 19.70 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 113.80M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 914 847 7000 | |||
| Address | 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 | |||
| Website | www.regeneron.com | |||
| Country | United States | |||
| Year Founded | 1988 | |||
| Profitability | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 32.27% | |||
| Profit Margin | 30.14% | |||
| Management Effectiveness | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 8.49% | |||
| Return on Equity | 16.26% | |||
| Income Statement | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 12.58B | |||
| Total Revenue (TTM) | 13.12B | |||
| Revenue Per Share | $115.27 | |||
| Gross Profit (TTM) | 6.86B | |||
| EBITDA (TTM) | 4.65B | |||
| EBIT (TTM) | 4.23B | |||
| Net Income (TTM) | 3.95B | |||
| Net Income Avl. to Common (TTM) | 3.95B | |||
| Total Revenue Growth (Q YOY) | 0.58% | |||
| Earnings Growth (Q YOY) | -3.13% | |||
| EPS Diluted (TTM) | 34.75 | |||
| EPS Diluted Growth (Q YOY) | -2.87% | |||
| Balance Sheet | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 10.84B | |||
| Cash Per Share (Q) | $95.30 | |||
| Total Current Assets (Q) | 19.48B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 25.97B | |||
| Current Ratio (Q) | 5.690 | |||
| Book Value Per Share (Q) | $242.47 | |||
| Total Assets (Q) | 33.08B | |||
| Total Current Liabilities (Q) | 3.42B | |||
| Total Debt (Q) | 2.79B | |||
| Total Liabilities (Q) | 7.11B | |||
| Total Common Equity (Q) | 25.97B | |||
| Cash Flow | REGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -3.19B | |||
| Cash from Financing (TTM) | -1.79B | |||
| Net Change in Cash (TTM) | -381.60M | |||
| Levered Free Cash Flow (TTM) | 2.75B | |||
| Cash from Operations (TTM) | 4.59B | |||
